N-butyl-N-methyl-8-bromooctanamide | 134414-26-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-butyl-N-methyl-8-bromooctanamide
• 英文别名: 8-bromo-N-butyl-N-methyl-octanamide；8-bromo-N-butyl-N-methyloctanamide
• CAS: 134414-26-9
• 化学式: C₁₃H₂₆BrNO
• 分子量: 292.26
• InChiKey: IYNBXSANKHOFMF-UHFFFAOYSA-N

物化性质

• 沸点：
  358.3±25.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-butyl-N-methyl-8-bromooctanamide 在 palladium on activated charcoal 氢气 、 triethylamine tris(hydrogen fluoride) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  A designed antagonist of the thyroid hormone receptor

  摘要：

  We synthesized an analogue of the thyromimetic GC-1 bearing the same hydrophobic appendage as the estrogen receptor antagonist ICI-164,384. While having reduced affinity for the thyroid hormone receptors compared to GC-1, it behaves in a manner consistent with a competitive antagonist in a transactivation assay. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00521-2
• 作为产物：
  描述：

  8-溴辛酸 在 三正丁胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.67h， 生成 N-butyl-N-methyl-8-bromooctanamide
  参考文献：
  名称：

  Synthesis and Antiestrogenic Activity of Diaryl Thioether Derivatives

  摘要：

  The reaction of 1,2-diarylethanol and mercapto side chain catalyzed by ZnI2 was used as a key step in the short (three to five steps) and efficient synthesis of 17 diaryl thioether derivatives. Several of these compounds contain a methyl butyl amide chain and an hydroxyaryl moiety, respectively, for antiestrogenic activity and binding affinity on estrogen receptor. No binding affinity for crude cytosolic preparation of the estrogen receptor was observed for compounds without phenolic group, while a low affinity (0.01-0.05%) was measured for mono- or diphenol derivatives. Like the pure steroidal antiestrogen EM-139, these novel nonsteroidal compounds did not exert any stimulatory effect on cell proliferation of (ER(+)) ZR-75-1 human breast cancer cells and partially reversed the amplitude of the stimulatory effect induced by estradiol on this (ER(+)) cell line. No proliferative or antiproliferative effect on (ER(-)) MDA-MB-231 human breast cancer cells was also observed for three of these compounds (39-41). Among the newly synthesized nonsteroidal compounds, the thioether derivative 41 (N-butyl-N-methyl-13,14-bis(4'-hydroxyphenyl)-12-thiatetradecanamide), with a long methylbutylalkanamide side chain and a diphenolic nucleus, was selected as the best antiestrogenic compound. However;this compound was 100-fold less antiestrogenic in (ER(+)) ZR-75-1 cells than the steroidal antiestrogen EM-139.

  DOI：

  10.1021/jm00034a009

文献信息

• 19.fwdarw.nor.fwdarw.steroids
  申请人：Roussel Uclaf

  公开号：US05149696A1

  公开（公告）日：1992-09-22

  Novel 19-nor-steroids of the formula ##STR1## wherein the A and B rings have a structure selected from the group consisting of ##STR2## having hormonal properties and their preparation and intermediates.

  这是一种公式为 ##STR1## 的19-去甲基甾体类化合物，其中A和B环结构选自以下组合：##STR2## 具有激素特性，以及其制备方法和中间体。
• 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives
  申请人：Schering AG

  公开号：US20030171345A1

  公开（公告）日：2003-09-11

  This invention relates to 11&bgr;-(para-substituted)phenyl-estra-1,3,5(10)-trienes with a straight-chin or branched-chain, optionally partially or completely halogenated alkyl radical or alkenyl radical in each case with up to 5 carbon atoms, an ethinyl radical or prop-1-inyl radical in 8&bgr;-position. The new compounds can be used for contraception in men and women, without influencing other estrogen-sensitive organs, such as the uterus or the liver. They are also suitable for the treatment of benign or malignant proliferative diseases of the ovary, such as ovarian cancer and granulosa cell tumors.

  本发明涉及具有直链或支链、选定的部分或完全卤代烷基或烯基基团，每种基团中含有高达5个碳原子的11β-(对取代)苯基雌三烯-1,3,5(10)-烯，以及在8β-位上的乙炔基或丙-1-炔基。这些新化合物可用于男女避孕，而不影响其他雌激素敏感的器官，如子宫或肝脏。它们还适用于治疗卵巢的良性或恶性增生性疾病，如卵巢癌和颗粒细胞瘤。
• 19-nor-steroids
  申请人：Roussel Uclaf

  公开号：US05290771A1

  公开（公告）日：1994-03-01

  The novel compounds of the invention are 19 nor-steroids of the formula: ##STR1## Where A, B, C, D, X, Y, Z, R.sub.17, and R.sup.1 are as defined in the specification, having hormonal properties and their preparation and intermediates.

  本发明的新化合物是具有激素性质的19-去甲基类固醇，其化学式为：##STR1## 其中，A、B、C、D、X、Y、Z、R.sub.17和R.sup.1的定义如规范所述，以及它们的制备方法和中间体。
• 19-Nor-steroids
  申请人：Aventis Pharma S.A.

  公开号：US06790971B1

  公开（公告）日：2004-09-14

  A 19-nor-steroid having a formula selected from the group consisting of wherein the A and B rings have a structure selected from the group consisting of having hormonal properties and their preparation and novel intermediates.

  一种19-去甲基类固醇，其化学式从以下组中选择，其中A环和B环具有激素特性的结构，以及它们的制备和新型中间体。
• THYROID HORMONE ANALOGUES AND METHODS FOR THEIR PREPARATION
  申请人：The Regents of the University of California

  公开号：EP1089968B1

  公开（公告）日：2005-04-20